Notably, our study identified an increased frequency of HER2-DC1 in the treated primary tumors and their migration, with prolonged survival, into the untreated distant tumors following HER2-DC i.t. and anti-HER2 antibodies combination treatment in a HER2pos BC model. This evidence concerns the gene ERBB2 and breast cancer.